Cartiva Lawsuit Update: Where MDL 3172 Stands in October 2026

Last updated: October 22, 2026

Current status: As of October 22, 2026, the federal Cartiva litigation, MDL No. 3172, is in its early pretrial stage in the U.S. District Court for the Eastern District of Arkansas before Chief Judge Kristine G. Baker. The Judicial Panel on Multidistrict Litigation’s October 1, 2026 report lists 21 Cartiva actions pending. After an August 26, 2026 organizational hearing, the court appointed leadership for both sides. No bellwether trial schedule appears in any public court filing we reviewed, and no global settlement has been publicly announced. The claims that the implant is defective are allegations that the manufacturer disputes, and causation has not been decided in court.

Chief Judge Kristine G. Baker is not related to Robert B. Baker or to Baker Legal Team.

What Has Happened in the Cartiva MDL So Far?

Here is the court record, newest events first. Each entry comes from the court’s own MDL 3172 page, the Judicial Panel on Multidistrict Litigation, or the FDA, except where another source is named.

Date	What happened
October 1, 2026	The Judicial Panel on Multidistrict Litigation’s monthly report lists 21 actions pending in MDL 3172, the same count as its July 1, 2026 report.
August 31, 2026	The court enters an Initial Management Order appointing plaintiff and defense leadership (order date as reported by AboutLawsuits; appointments listed on the court’s MDL page).
August 26, 2026	Chief Judge Baker holds the initial organizational hearing in Little Rock.
April 16 to June 24, 2026	The Panel enters Conditional Transfer Orders CTO-2 through CTO-6, moving additional federal Cartiva cases into the MDL.
June 22, 2026	The court issues a letter order setting the August 26 organizational hearing and asking both sides for leadership and scheduling proposals.
February 18, 2026	The court enters its Order Upon Transfer. It sets filing rules for the MDL and stays all discovery until the initial conference.
February 6, 2026	The Panel enters Conditional Transfer Order CTO-1, the first order moving related cases into the MDL.
February 5, 2026	The Panel centralizes the federal Cartiva cases in the Eastern District of Arkansas as MDL No. 3172, Case No. 4:26-md-03172-KGB, assigned to Chief Judge Kristine G. Baker.
January 29, 2026	The Panel hears argument on whether to centralize the cases.
October 31, 2025	Plaintiffs ask the Panel to centralize the federal Cartiva lawsuits.
December 4, 2024	The FDA posts the Class 2 recall record for the Cartiva Synthetic Cartilage Implant.
October 31, 2024	Stryker issues an urgent medical device recall notice on behalf of Cartiva, Inc., covering every implant lot distributed from July 2016 to October 2024.

Consolidation does not merge your case with anyone else’s. It means evidence gathering happens once, in front of one judge, instead of separately in courts around the country. Your medical history and your losses still decide your own claim.

What Happened at the August 26, 2026 Organizational Hearing?

Chief Judge Baker’s June 22 letter order set the agenda for the hearing. It asked the parties to address liaison counsel, plaintiff and defense leadership, the timing of motions, a discovery plan, protective orders, and whether the defense intends to challenge jurisdiction, service, or which companies are named.

After the hearing, the court appointed Alex C. Davis and Randi Kassan as plaintiffs’ co-lead counsel, Paul J. James as plaintiffs’ liaison counsel, and a plaintiffs’ steering committee. Sean K. Burke and Dana J. Ash serve as defense co-lead counsel, with Mr. Burke also acting as defense liaison counsel.

Co-lead counsel’s firm has reported that the defense told the court it plans to move to dismiss the cases on federal preemption grounds. Until those motions are filed, briefed, and decided, the pretrial schedule will largely turn on them. We will update this page when the court puts those decisions in writing.

If you are facing revision or fusion surgery, the removed implant can matter as evidence. Our guide to Cartiva implant records and evidence explains how to ask that it be preserved.

Why Did the Cartiva Cases End Up in Arkansas?

The Panel picked the Eastern District of Arkansas because relevant documents and witnesses are likely near Memphis, Tennessee, where Wright Medical Group, Cartiva’s corporate successor, had its headquarters.

That corporate history matters because liability can follow a company through a sale. Cartiva, Inc. developed the implant, which the FDA approved in 2016. Wright Medical acquired Cartiva in 2018, and Stryker acquired Wright Medical in 2020, four years before the recall. Your attorney names the companies that controlled the device when you had your surgery.

Is the Cartiva MDL the Same as a Class Action?

No. In a class action, one or a few named plaintiffs represent the whole group, and class members usually share in a single resolution regardless of how badly each person was hurt.

A mass tort MDL works differently. Each person files an individual lawsuit. Pretrial work such as evidence gathering is shared across all plaintiffs, but every claim keeps its own facts, its own injuries, and its own outcome. That is why a patient who needed two revision surgeries is not lumped together with a patient whose implant was flagged early.

Because each claim stands on its own record, its value depends on individual facts such as surgeries, lost work, and permanent loss of motion. Our guide to what a Cartiva claim is worth explains those factors.

What Does a Bellwether Trial Test?

Once an MDL grows large enough, the court and the parties often choose a small number of representative cases to try first. These are bellwether trials. Their verdicts do not bind anyone else’s case, but both sides use them to see how juries respond to the evidence, and that information often shapes later settlement discussions, including for cases that are never tried.

MDL 3172 has not reached that stage. The court’s public orders so far cover transfer, filing rules, and leadership. As of October 22, 2026, no bellwether selection process or bellwether trial date appears in any public court filing we reviewed.

A few individual Cartiva lawsuits filed before the MDL received trial dates in their own courts. Those are not MDL bellwether trials, so treat any specific bellwether date you read elsewhere with caution unless it cites a court order.

What Did the Cartiva Recall Cover, and What Do the Failure Figures Show?

On October 31, 2024, Stryker issued an urgent medical device recall notice on behalf of Cartiva, Inc. It covers every lot of the Cartiva Synthetic Cartilage Implant in all four sizes (6, 8, 10, and 12 mm) distributed from July 2016 through October 2024. The FDA classified it as a Class 2 recall, posted the record on December 4, 2024, and lists the recall as open.

According to the notice, post-market reports and recently published data suggest patients may experience revision, removal, subsidence, displacement, pain, nerve damage, and fragmentation at higher rates than the data behind the device’s 2016 approval showed. The notice asked facilities to stop using, quarantine, and return unused implants. It did not advise surgeons to remove implants already in patients. It asked them to keep monitoring those patients.

Two figures come up often, and they measure very different things:

• The approval study. In the FDA’s summary of the study behind the 2016 approval, 152 patients were treated with Cartiva. By 24 months, 14 of them (9.2 percent) had the implant or hardware removed.
• The adverse-event reports. A 2024 review by Radcliffe and Roukis of 236 adverse-event reports in the FDA’s MAUDE database found implant removal in 73.7 percent of those reported cases. That figure describes only patients whose problems were reported to the FDA. It is not a failure rate for all Cartiva patients.

Plaintiffs allege the implant failed in ordinary use at higher rates than the approval study suggested. The manufacturer disputes these allegations, and causation has not been decided in court. For a full comparison of the published studies, see our analysis of Cartiva implant failure rates.

A recall does not prove legal liability on its own, and it is not required for a valid claim. It is a public record your attorney can build from instead of starting cold with your surgical file.

Can You Still File a Cartiva Lawsuit?

Whether you can still file depends mainly on the statute of limitations where your claim arises, and some states also apply a statute of repose. The recall date alone does not reset either deadline, and our guide to Cartiva lawsuit filing deadlines explains how those rules work and what the MDL does and does not change.

What Does Baker Legal Team Confirm Before Taking a Cartiva Case?

Before accepting a case, the firm confirms that you received a Cartiva implant, that complications followed, and that the implant led to more treatment such as revision, removal, or fusion surgery. Our guide to whether you qualify for a Cartiva lawsuit walks through each point, including what does not disqualify you.

Why Is a Board Certified Trial Lawyer Handling These Cases?

The Florida Bar has certified Robert B. Baker in Civil Trial Law, a distinction held by fewer than one percent of Florida attorneys.

He has worked inside multidistrict litigation before. Robert served as State Liaison Counsel for Rhode Island in the multidistrict breast implant litigation, coordinating claims against Dow in Massachusetts and Rhode Island. The Cartiva MDL runs on the same basic structure: one lead court, shared evidence, and claims that rise or fall on their own facts.

Robert B. Baker is not related to Chief Judge Kristine G. Baker, who presides over MDL 3172. Baker Legal Team also handles other active mass tort cases.

What Are the Most Common Questions About the Cartiva MDL?

Do I need an existing lawsuit to join the MDL?

You do not need an existing lawsuit to join the Cartiva MDL. A new federal Cartiva case becomes part of MDL 3172 for pretrial proceedings once it is filed and transferred or filed under the court’s procedures. Whether your case belongs in the federal MDL or in a state court is a separate question, explained in our comparison of the Cartiva MDL and state court.

Does it hurt my case if my symptoms started before the October 2024 recall?

Symptoms that started before the October 2024 recall do not by themselves hurt your case. The recall date is not the line that decides eligibility. The key questions are whether you received the implant, what complications followed, and whether the device led to more treatment.

Will bellwether trials happen before I can file?

Bellwether trials do not need to happen before you can file. Filing and the trial schedule run on separate tracks, and waiting for a trial date only shortens the time your attorney has to gather records and meet filing deadlines.

What if I already reached a settlement directly with Stryker or a hospital?

Whether a prior settlement with Stryker or a hospital affects your options depends heavily on what you signed. A free case review can tell you whether that agreement limits what you can do now.

How long does a Cartiva case usually take?

How long a Cartiva case takes depends on how the MDL’s motions and any bellwether process unfold, so no one can give a reliable timeline yet. Our guide to what happens after you file a Cartiva lawsuit walks through each stage from your side of the case.

What Does Filing Now Buy You Before the Bellwether Results Land?

Filing now protects your claim from filing deadlines and gives your attorney time to gather your medical and surgical records. That file is built before any bellwether results arrive, rather than in a rush afterward.

You don’t need to become an expert in multidistrict litigation. You need an attorney who has coordinated multidistrict claims before.